专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008005511A8 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION 审中-公开
标题翻译： HEPATITIS C VIRUS REPLICATION的新型抑制剂
公开(公告)号：WO2008005511A8
公开(公告)日：2009-03-19
申请号：PCT/US2007015530
申请日：2007-07-05
申请人： INTERMUNE INC , ARRAY BIOPHARMA INC , BLATT LAWRENCE M , SEIWERT SCOTT , BEIGELMAN LEONID , KERCHER TIMOTHY , KENNEDY APRIL L , ANDREWS STEVEN W
发明人： BLATT LAWRENCE M , SEIWERT SCOTT , BEIGELMAN LEONID , KERCHER TIMOTHY , KENNEDY APRIL L , ANDREWS STEVEN W
IPC分类号： C07D231/56 , A61K31/4035 , A61K31/416 , A61K31/437 , A61P31/14 , C07D403/14 , C07D471/04
CPC分类号： C07D403/14 , C07D231/56 , C07D471/04
摘要： The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a, subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a subject compound, The embodiments provide compounds of the general Formula (III), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译：实施方案提供了通式（I）的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案提供了通式（II）的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案提供了通式（III）的化合物，以及包含药物组合物的组合物，其包含受试者复合。实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

2. 发明申请

WO2008005511A3 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION 审中-公开
标题翻译： HEPATITIS C VIRUS REPLICATION的新型抑制剂
公开(公告)号：WO2008005511A3
公开(公告)日：2008-07-31
申请号：PCT/US2007015530
申请日：2007-07-05
申请人： INTERMUNE INC , ARRAY BIOPHARMA INC , BLATT LAWRENCE M , SEIWERT SCOTT , BEIGELMAN LEONID , KERCHER TIMOTHY , KENNEDY APRIL L , ANDREWS STEVEN W
发明人： BLATT LAWRENCE M , SEIWERT SCOTT , BEIGELMAN LEONID , KERCHER TIMOTHY , KENNEDY APRIL L , ANDREWS STEVEN W
IPC分类号： C07D231/56 , A61K31/4035 , A61K31/416 , A61K31/437 , A61P31/14 , C07D403/14 , C07D471/04
CPC分类号： C07D403/14 , C07D231/56 , C07D471/04
摘要： The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a, subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a subject compound, The embodiments provide compounds of the general Formula (III), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译：实施方案提供了通式（I）的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案提供了通式（II）的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案提供了通式（III）的化合物，以及包含药物组合物的组合物，其包含受试者复合。实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

5. 发明专利

ES2494590T3 Compuestos de N-(1H-Indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida sustituida como inhibidores de cFMS 未知
公开(公告)号：ES2494590T3
公开(公告)日：2014-09-15
申请号：ES10798683
申请日：2010-12-20
申请人： ARRAY BIOPHARMA INC
发明人： BOYS MARK LAURENCE , BRADLEY MICHAEL F , DELISLE ROBERT KIRK , HENNINGS D DAVID , KENNEDY APRIL L , MARMSATER FREDRIK P , MEDINA MATTHEW DAVID , MUNSON MARK C , RAST BRYSON , RIZZI JAMES P , RODRIGUEZ MARTHA E , TOPALOV GEORGE T , ZHAO QIAN
IPC分类号： C07D471/04 , A61K31/437 , A61K31/4985 , A61P9/00 , A61P19/08 , A61P29/00 , A61P35/00 , C07D519/00
摘要： Compuesto que tiene la fórmula general I o una sal farmacéuticamente aceptable del mismo, en el que: R1 es hetAr1CH2-, hetAr2CH2-, (cicloalquilo C3-6)-CH2-, tetrahidropiranilCH2-, bencilo que está opcionalmente sustituido con alcoxi(C1-4), o (N-alquilo C1-3)piridinonil-CH2- que está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de alquilo(C1-6); hetAr1 es piridilo opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de entre alquilo(1-6C), alcoxi(C1-4), halógeno, hetCyc1, hetCyc1-CH2-, aminoalcoxi(C2-4), [di(alquil C1- 3)amino]alcoxi(C2-4), dihidroxialcoxi(C3-4), hetCyc2O-, hetCyc2a15 alcoxi(C1-2) y OH; hetCyc1 es un heterociclo de 6 miembros que tiene 1-2 átomos de N anulares, y opcionalmente sustituido con NH2; hetCyc2 y hetCyc2a 20 son independientemente un heterociclo de 5-6 miembros que tiene 1-2 átomos de N anulares y opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de alquilo(C1-6), OH, y halógeno; hetAr2 es un anillo heteroarílico de 5 miembros que tiene 2-3 heteroátomos anulares seleccionados independientemente de entre N, S y O en el que al menos uno de dichos heteroátomos es N, en el que dicho anillo está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de entre alquilo(C1-6), hidroxialquilo(C2-4), dihidroxialquilo(C3-4), (cicloalquilo C3-6)CH2-, hetCyc3, hetCyc3aalquilo(C1-2), y bencilo opcionalmente sustituido con alcoxi(C1-4); hetCyc3 y hetCyc3a son independientemente un anillo heterocíclico de 6 miembros que tiene 1-2 átomos de N anulares y opcionalmente sustituido con un halógeno; R2 es alquilo(C2-4), ciclopropilo, OMe, I o Br; R3 es H o Cl; R4 es H o CN; R5 es H, halógeno, OH, hetAr3, hetAr4, N-(alquilo C1-3)piridinona, hetAr5, hetCyc4, hetCyc5C(>=O)-, hetCyc6(alquilo C1-4)-, hetCyc7alcoxi(C1-4), (hetCyc8)-O-, hetCyc940 alcoxi(C1-4), (alcoxi C1-3)alcoxi(C1-4), hidroxialcoxi(C1-4), dihidroxialcoxi(C2-4), difluoroaminoalcoxi(C1-4), [di(alquil C1-3)amino]alcoxi(C1-4), [(alcoxi C1-4)carbonilamida]difluoroalcoxi(C1-4), (alquilo C1-4)C(>=O)NHalquiltio(C2-4)-, (alquilo C1-4)OC(>=O)-, (alquilo C1-4)C(>=O)-, hidroxialquilo(C1-4), [hidroxialquil(C2-4))amino]-alquilo(C1-4), [(alcoxi C1-4)(alquilo C1- 4)amino]alquilo(C1-4), [di(alquilo C1-4)amino]alquilo(C1-4), R'R"NC(>=O)-, alquiltio C1-6, benciloxi, [hidroxialcoxi(C1-4)]alcoxi(C1-4), o [(alqueniloxi C2-4)alcoxi(C1-4)]alcoxi(C1-4).

8. 发明专利

HK1190709A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS III N-(1H--4-)[12-A]-3- 未知
公开(公告)号：HK1190709A1
公开(公告)日：2014-07-11
申请号：HK14103774
申请日：2014-04-22
申请人： ARRAY BIOPHARMA INC
发明人： BOYS MARK LAURENCE , DELISLE ROBERT KIRK , HICKEN ERIK JAMES , KENNEDY APRIL L , MARESKA DAVID A , MARMSATER FREDRIK P , MUNSON MARK C , NEWHOUSE BRAD , RAST BRYSON , RIZZI JAMES P , RODRIGUEZ MARTHA E , TOPALOV GEORGE T , ZHAO QIAN
IPC分类号： C07D20060101 , A61K20060101 , A61P20060101
摘要： and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

9. 发明专利

NZ601376A Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors 未知
公开(公告)号：NZ601376A
公开(公告)日：2014-03-28
申请号：NZ60137610
申请日：2010-12-20
申请人： ARRAY BIOPHARMA INC
发明人： DELISLE ROBERT KIRK , BRADLEY MICHAEL F , RODRIGUEZ MARTHA E , TOPALOV GEORGE T , BOYS MARK LAURENCE , HENNINGS D DAVID , MARMSATER FREDRIK P , RIZZI JAMES P , MEDINA MATTHEW DAVID , MUNSON MARK C , KENNEDY APRIL L , ZHAO QIAN , RAST BRYSON
IPC分类号： C07D471/04 , A61K31/437 , A61K31/4985 , A61P9/00 , A61P19/08 , A61P29/00 , A61P35/00 , C07D519/00
摘要： 601376 Disclosed is a compound of formula I such as N-(1-benzyl-3-iodo-1H-indazol-4-yl)-7-(2-methoxyethoxy)imidazol[1,2-a]pyridine-3-carboxamide, which is useful for treating bone-related diseases, cancer, autoimmune diseases and inflammatory diseases.

10. 发明专利

HK1176928A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS CFMS N-(1H--4-)[12-A]-3- 未知
公开(公告)号：HK1176928A1
公开(公告)日：2013-08-09
申请号：HK13103717
申请日：2013-03-25
申请人： ARRAY BIOPHARMA INC
发明人： BOYS MARK LAURENCE , BRADLEY MICHAEL F , DELISLE ROBERT KIRK , HENNINGS D DAVID , KENNEDY APRIL L , MARMSATER FREDRIK P , MEDINA MATTHEW DAVID , MUNSON MARK C , RAST BRYSON , RIZZI JAMES P , RODRIGUEZ MARTHA E , TOPALOV GEORGE T , ZHAO QIAN
IPC分类号： A61K20060101 , C07D20060101 , A61P20060101
摘要： Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4 and R5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式